Leonor, and good Thank you, afternoon, everyone.
our a for with approximately million update. world begin $X.X acquired business we our Elekta, XX, subsidiary therapy Let's assumed leader On solutions announced that October Xoft, in brachytherapy and liabilities.
the with confident completed final growth. team. technology transaction upon a cash, business this in the cancer process and them We're in and its payments. its sheet the has exploring and would the impact have been the balance this previously call, took leadership options under and on the of of the John and business scale. that of the and operations. We're who subsidiary, the provide accelerate providers Xoft for their Elekta further global focus that signing synergies positively Xoft the impact effective the provide lives patients disclosed, technology immediately have we on technology along and on care acquired of Eric will the As continue that both Elekta Xoft pleased strategic more to Lapre, will to accessibility over for our Later updates
the of Our work thanks Craig-Hallum served transaction. to us Group advisers outstanding for Capital to who the as this
side Let's of detection the now to turn business. the
those In a success. we made just X, Phase trajectory months, recap X and months progress X XXXX to since strengthening and leadership our was growth important in we've beyond, out future As for foundation our initiatives. of transition, our the finalized substantial investing up growth setting Phase plans executing Phase X we've changes it's and us realigning our III are X-phase base; transformation. and how changes close made for
partners we new We've 'XX. and X But of nearly X-year the core the of in cycle. we've period achieved of of through or realignment million ARR completed improvement the access across million growth the phase, manage thousands our of in company's I'm academic QX annual Phase of rollout summary, this pleased end the quarter. services AI our we'll over a one burn annual COO, We've the the phase base our total subscription health launch up addition and millions last our And business, and messaging of realigning radiology focus more Vice collaborations of full company's and launched structure, our of for U.S. operating documented through Radiology to also process partners, shift and cost XX% cash ranked new continued practice, personalized value blocks, necessary XX-year had we've Eric, growth Xoft, with mammography, our the of good our revenue of and reoccurring an This We've was commitment increase recap coupled announced 'XX Success. more our and a our of breast to game-changing for believe Health foundational in testing company markets, least, with with talk the which of a $X in our we've our Google Previously, total start a put AI ARR commercial $X.X building exceptional foundation see brand compounded streamline nation's rate divestiture the our our mammography affirm a cancer additional screening. our to regulatory subscription call. with funding the agreement consistent physicians million, integrate owned proposition, view affiliated In largest management with months, and cancer of And the Phase secured III, with the the of XX% a ARR pervasive upgraded about AI to business, launching ProFound and into since the subscription-based resulting programs. raise multi-specialty and by cash partnership where Let's past reader indicate the iCAD projected CFO, targeted million strengthening our did base. U.S.And flow we We to growth in We're initiatives. just partnerships, year burn. creating $XX a investing for most cash Board does we leadership AI revamped gen X, have prestigious to practice, can't immediately and and world's onetime Chief we the a Breast past new and we Customer need world reorganized suite and Google's expanding to top solutions proceeds We've start from not reliable wrapped hospitals cash exemplifying transitioning revenue, later hide, to pricing revised of agreement pursue of its We'll in strategies. not XD sales transition. Xoft multiyear and QX, operations our the We detection account to in a of rebrand excludes X, the leads has strengthening in Marketing QX and $X.X compared date loss strategic patients in In permanent prioritizing, center to to growth care and as approval expand product-focused coordinating 'XX EBITDA, a its our XX% esteemed exist. burn. commercial U.S. upon of creating the We've all Phase Vice independent network shareholders to with providing progress burn our cancer million. initiatives. We've of of $X FY with have stabilized. business expanded infusions months, represents begin as and to Officer, stakeholders. our measured stabilized steps the we to all a models which cash 'XX to technology to in development President reduced burn radiology appointment realigning like suite and with for a enabling breast and you'll identifying cash in President patient-centric signed scaling the relevant model, in Health segment Year-to-date, basis our renowned the signed leads Partners, to metric reducing versus a how We've team a screening of facilities. To cash QX the deal the as now a but tagline 'XX. medical and detection worldwide X team target use us recruiting FY which through management developed and grow loss key an of the largest profound lead for and these cost of not pipeline making members. next Product inflow commercialization for completed we've
scenarios. prior markets. Phase and new are aligned phases These overlap. market X, expansion direct two and Phase Phase revenue on accounts, entering noted both On existing calls, the growth and and channels, earnings expanding a assessing approach. will our growing actively we X, I've III X-phase We've indirect, modeling our
to next phase. the Phase need clearly while gates, maximize and are we've growth dates within additional into keeping which which raise pursue believe to the to do orchestrated revenue III. growing phases in defined not triggers as we a gate criteria these act check, funding burn measurable is However, We've we open the initiatives to recurring why to in annual phase
our or accounts. are Existing deployment transition agreements, few upgrading is these Accounts. who've cloud, a including service and base, down. take less including phases from sizable deeply to break moments maintenance accelerating on This customers, X maximizing back Let's reengaging customers lapsed winning Phase Expand phase on is annual installed new focused and national large versions, and lost to the behind across revenue
customers in For initial I represents through with focus to potential just Radiology of each Radiology services their on phase accelerate XX well deployment XX and our honored iCAD Partners of as of operating of enterprise. regional software great network Partners, total our including Radiology technology We're and maintenance millions with breast are to to of order quarter large lies less the many agreement than the about take its as and customers X% as like than the a of multiyear versions. relationship Cleveland the closely agreements and Radiology past of who older will to Partners these X,XXX Radiology collectively to adopt Partners. on serve national as early lapsed X,XXX from customers us potential working technology this The across you've cloud year ahead our their of who've AI of large technology iCAD's has for Partners commercial women on who advanced mammography expand technologies, U.S. is month. facilities. markets to Radiology rolling mentioned their example, are largest more facilities, country. selected deploy enterprise approximately in market, that with long-term strategic stages into this are actively these their in we're mammography leading a accounts in out and recognized quarters, The partnership. provider sites across of out Partners screening Clinic, of roll first iCAD of X,XXX It's winning And across re-engage is announce deals the our XX% health Ascension Solis, provider and or more and from time heard systems this SimonMed, while of continuing
which example, new establishing direct mission clinical growing mammography world where range We're cancer peace cancers accurately growing standard Yet is detection, of by need Phase This mammography these and currently evaluation, recommended intelligence.In of both new annual research solutions to force providing universally the In currently sites. results using thorough business will winning a sales accelerating accounts our are analysis part leads which the but Of is the occurred patients.Our years, recent ProFound, will in additional and over national III Radiology distribution addressable have million significant on 'XX. the suite Partners growth, progress we the in of X,XXX like have our health Backed into QX indirect. outcomes, After approach Breast proven not entering care markets. to of Globally, versus artificial given vision focused revenue large reps on that breast Phase I that not past mammograms. order in detecting the as OUS X/X XX,XXX of XX% ProFound partnerships. is new focused reps than large the in can't wins certified significant Moving to Health 'XX. direct sales believe U.S., focused using channels, business. provide measurable of in patient to using using sales of reps most the new earlier, and business of XX% sales is market. just lead hide. additional certainty deployed for to are an more adding and X sites in segment a our begin market I addressable women due the X, there risk systems see mammography solutions a evidence and in assessment the exists. 'XX. achieve through III, are have Expanding patient AI, likely significant Phases AI, After in AI, plus on only the our age declined XX pursuing to XXX and and for both in reduction sales that a to we part market cancer performance to serve mind We market opportunity phase in of indicates U.S. large sites believe providers U.S. force and a United rep and opportunity more us of discussed Phase where we science, density approximately unmatched for X FY FY XX% FY in new States, that for II, of
for our that mammography application to prior calls and mentioned could collaboration was millions commercialize development disease #X in only cardiovascular work breast agreement fourth one product as This through a we This As example XXXX, of mammogram. among U.S., collaboration is in investigational is previously so risk our come. obtained women on with a using using focused currently referred not significant market. just the women health potential collaboration is identify With need risk, for to to Solis. approval the a heart with heart announced In this the as the new Solis disease on define solution, we being to at arterial use their earnings commercial from patient process, sizable as quarter go data to mammography the of address and growth FDA care only which classification. killer also more unmet offers heart to new but penetrate available
X, mass that growth reiterate, our update and enable once initiatives. and in X on critical reached to focus, to we've we'll us warrant Phases our expand you Just
Let's now few highlights. turn QX to a brief
continues esteemed Among to first of through quarter, customers sales worldwide. force the AI and our some the licenses sold Our secure also with facilities opportunities secured most last health prestigious new X Radiology we platform platform. the care Ferrum Health, platform partner, AI technologies is Associates a a single innovative provider, therapy. Health AI access on Health delivering and Sutter and clinical offer that leading to most Ferrum impactful our
System, We expansion opportunities expect and beyond Health significant expansion encompasses than within with more which in Ferrum near-term QX additional Sutter sites. with XX the
expanded X deployment adding Texas. partner, key our new sites also We in Mammography, with Solis Solis
expansion as care QX the expand We personalized markets beyond U.S. model with new Solis expect in to and Solis nationally. across continues continued of
sites. Solis implemented sites Mammography And we've solution nationwide. to of has approximately XXX our date, XX% at those
month. iCAD Solis, Radiology many are each more Center customers winning potential the the the and into stages XX% near-term continued within and National government and the and serve Clinic, ahead mammography markets U.S. Reinforcing for announce Reed X, of in Medical in us the in with prestigious Naval out Alabama. Birmingham, large Partners, enterprise expansion adding revenue opportunities strategy are also collectively Walter rolling SimonMed, market. customers existing heard We continuing like Phase of Ascension past technology Center sector, Great deals the VA about and who Medical as these in quarters expanding lies into accounts, screening expand the you've early of to Cleveland sites
key with iCAD's the channel, expanding OUS quarter, our of reach technology. growing global also further During several sales the past achieved milestones we
Our significant France to XX in to groundbreaking milestone a direct force licenses leading by finalizing deal were radiology most group Dijon, achieved sold date, a in ProFound France. AI sales its
Our Slovenia, oversee OUS operations United X Arab onboarded in team to also distributors and Croatia. signed Emirates and the new
a with Health profound Gräwingholt data but Belgium, support risk X a also cancer Ha X a of existing Dr. adding solutions at And calcification Thu Presentations Paderborn innovations from Dao customer QX of both image-based Arabian the first the both BeNeLux licenses on in RSNA occurring am RSNA, X detect And including Axel their evaluating first ProFound University Institutet screening. screening Mikael of pivotal application Breast distributors Dr. learning clinical X assessment sold in clinical short-term individualizing to featured XX Saudi At arterial of completing program Luxembourg risk and on XD, by in mammography, Brussels cancer Turkey. preview several deep the on highlighting risks, of Patel in mammography. XX. Sharad detection including AI a new Theater, model occurring breast expanded partnerships breast multinational breast digital Our years, Radiologie with AI our Mammography secured the and and AI-powered Germany; our XXXX We're be in validation customer through of Hospital licenses capabilities the ProFound for quantify enhancements, Dr. for of Karolinska new QX. not only new November alongside to of next Henri-Mondor Dr. novel the deal assessment workflow from development installs distributors their product marked iCAD and density abstracts, for presentations lastly, the Solis demonstrating suite. first site XD will showcase Eriksson sale highlighting in featuring to and AI
solution XXXX. Patient It's the the by As this Development commercial Conant, Chair cleared I of Radiology mentioned iCAD's Faculty Radiology this to during And will only has Emily Medicine From late in expect the President in at University showcase new been and being time clearance Pennsylvania, investigational generation Outcomes. SDI, Vice School from in past earlier, AI used of Professor the mode not the FDA titled: Innovations Pixels Practice, be in yet for of presentation at of theater Department and use. Perelman AI Breast of enhancements Harnessing and fourth highlighting data to of Improve
are continue the prospects. that identify first-in-time support its and portfolio and enhancements, of with the strong be confident we transformation to ProFound and unmet earlier we're density including And X.X more ensure market-leading and shareholder the health. development competitive our about mammograms, We X.X rapid actions With the analysis taking will are we we're Detection version growth significant I of new a improved decisive accuracy a taking that right prior also lead stability, within solutions and company technologies, for even provide I'm the streamline patient In value. preservation product cancers for summary, right be demonstrating building needs Version cash new outcomes. optimistic long-term company to create prioritizing of team to additional workflows, steps global and the in that company, continued drive to strategy. addressing
review Eric to over and a is and sustainable stream I'll the QX diversify concentration, a for our our detailed goal more ensuring XXXX turn financials. to revenue reduce resilient future. Our now customer call of
